| Cat.No. | Name | Information |
|---|---|---|
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M9173 | Cilengitide TFA | Cilengitide TFA is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M13754 | OSU-T315 | OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
| M13752 | BIO-1211 | BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively. |
| M6905 | Leukadherin-1 | Leukadherin-1 is a allosteric activator of CD11b/CD18. Leukadherin-1 increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. |
| M6538 | BTT 3033 | BTT 3033 is a selective inhibitor of integrin α 2β 1. |
| M6363 | A-286982 | A-286982 is a potent inhibitor of the LFA-1/ICAM-1 interaction. A-286982 binds to the I domain allosteric site (IDAS). |
| M6018 | Tirofiban hydrochloride monohydrate | Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist |
| M5852 | Lifitegrast | Lifitegrast is an antagonist of integrin lymphocyte function associated antigen-1 (LFA-1). The IC50 of Jurkat T cells to icAM-1 was 2.98nM. Lifitegrast blocks the interaction between LFA-1 and ICAM-1, thereby reducing T cell activity and cytokine secretion. |
| M5619 | Eptifibatide | Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. |
| M5241 | GLPG0187 | GLPG0187 inhibited the progression of bone metastasis. Maximum efficacy of inhibition of bone metastasis was achieved when GLPG0187 was combined with the standard-of-care metastatic breast cancer treatments. |
| M3789 | ATN-161 TFA | ATN-161 TFA salt is a novel small peptide inhibitor of integrin α5β1; a beta integrin antagonist with antitumor activity. |
| M3074 | Tirofiban | Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. |
| M2976 | RGD | RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins. |
| M2362 | A-205804 | A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively. |
| M1618 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that specifically antagonizes Integrin (α4β7) and inhibits the binding of α4β7 to the intestinal mucosal cell adhesion molecule MADCAM-1. Vedolizumab is indicated for humanized mice. |
| M58678 | MORF-627 | MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC50 of 9.2 nM (measuring by human serum ligand binding assay). MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC50 of 8.3 nM. |
| M56036 | GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist. |
| M54412 | HSDVHK-NH2 | HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
| M54125 | Obtustatin | Obtustatin is a non-RGD disintegrin of 41 residues. |
| M54054 | Integrin Binding Peptide | Integrin Binding Peptide is derived by fibronectin. |
| M54039 | GRGDSPK | GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). |
| M54038 | Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA | Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. |
| M54021 | Cyclo(RGDyK) | Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
